MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
Last trade$52.53
Day change-$0.59 (-1.11%)
Day range$50.80 – $54.44
Volume167,586
Market cap$2.64B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for MBX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for MBX.
Recent news
Company coverage with links to the original publishers.
MBX Biosciences announced positive one-year data from its open-label extension study of canvuparatide, a once-weekly PTH replacement therapy for chronic hypoparathyroidism. The drug maintained a 57% responder rate at one year with a 90% retention rate, demonstrated sustained benefits in calcium homeostasis, kidney function, and bone metabolism, and showed no new safety signals. The company remains on track to initiate Phase 3 pivotal trials in Q3 2026.
AstraZeneca announced that its investigational drug eneboparatide (AZP-3601) met the primary endpoint in the Phase 3 CALYPSO trial for chronic hypoparathyroidism. The therapy demonstrated that 31.1% of patients achieved normal calcium levels and independence from vitamin D and calcium supplements at week 24, compared to 5.9% in the placebo group. The drug was generally well-tolerated, with benefits maintained through 52 weeks, though immunogenicity was observed in some patients.
MBX Biosciences announced preliminary Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug showing 7% mean weight loss at 8 weeks with good tolerability and potential for once-monthly dosing. The company also nominated MBX 5765, a novel four-agonist candidate for obesity, and achieved proof of concept for imapextide in post-bariatric hypoglycemia, though will not pursue further Phase 2b development of the latter to prioritize resources.
MBX Biosciences announced the appointment of Karen Basbaum as Chief Business Officer and issued her an equity inducement award of 130,000 non-qualified stock options with an exercise price of $32.29 per share. The options vest over four years with a 10-year term, approved by the board as a material inducement for her employment.
MPM BioImpact sold its entire 1.3 million share stake in MBX Biosciences, worth $14.8 million, during Q3 2025, just before the company's pivotal clinical trials and potential key milestones in 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.